Skip to main content
Equibles
PLX logo

PLX · Protalix BioTherapeutics, Inc.

Track PLX — free

Use PLX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about PLX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.38 +0.00 (+0.00%) At close · Aug 21
Market Cap
$191.76M
Shares
80.57M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.38 Open$2.39 Day$2.35–2.44 52W close$1.54–3.15 Avg vol 30d689K Short int3.9M · 4.8% float · 7.5d Short vol48% Last earningsAug 12, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Nov 11, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 12, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Buy Momentum Weak Sentiment Neutral Fundamentals Weak Quant / Vol Very High
      Market backdrop VIX 15.1 · calm Equity put/call 0.51
      Technical
      price trend
      Buy
      50 / 200-day cross No cross
      Price vs 200-day avg +7%
      above
      Price vs 50-day avg +3%
      above
      RSI (14) 51
      neutral
      MACD trend Negative
      52-week position 52%
      mid-range
      Momentum
      relative strength
      Weak
      1-month return 0%
      trailing
      6-month return −21%
      trailing
      YTD return +32%
      this year
      Relative strength −33%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 50d above 200d
      Institutional flow Flat
      0% holders QoQ · +18 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      4.81% of float · ▲ +4.4% MoM · 7.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      101 holders — near 3-yr high, broad support
      Squeeze score 71
      high risk · 0–100
      Fundamentals
      Weak
      Revenue growth −1%
      Y/Y
      Gross margin 8%
      expanding
      EPS growth −300%
      Y/Y
      Free cash flow $-13.6M
      Valuation P/E 9.9
      in line
      Balance sheet $13.8M
      net cash
      Quant / Vol
      risk profile
      Very High
      Volatility 65%
      annualized · 1-yr
      Max drawdown −40%
      past year
      ATR 4.9%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Latest guidance · from the 8-K filed May 13, 2026
      Total revenue in 2026 to range from approximately $78.0 million · Full-year 2026 $78M – $83M
      Full-year 2026 revenues from sales of Elfabrio without milestone · Full-year 2026 $33M – $35M
      Full-year 2026 revenues from sales of Elelyso · Full-year 2026 $20M – $23M

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Buy
      1 · 3 · 2
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      +7% Bullish
      Price vs 50-day avg
      +3% Bullish
      RSI (14)
      51 Neutral
      MACD trend
      Negative Bearish
      52-week position
      52% Neutral
      Market signals — smart money & positioning
      Mixed
      Trend (MA cross) No cross
      50d $2 › 200d $2 — 50d above 200d
      Institutional flow Flat
      0% holders QoQ · +18 funds added
      Insider flow Flat
      No net insider activity over 90 days
      Short interest Rising
      4.81% of float · ▲ +4.4% MoM · 7.5 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Multi-yr high
      101 holders — near 3-yr high, broad support
      Price context
      position in its 52-week range
      Range low $2 Now $2 · 52% Range high $3
      vs 200-day avg +7% vs 50-day avg +3%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Versus peers

      Biotechnology — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      PLX
      Protalix BioTherapeutics, Inc.
      this stock
      		$191.76M +32.2% -1.2% 9.9 4.8%
      VRTX
      Vertex Pharmaceuticals Inc / Ma
      		 $138.91B +20.9% +46.2% 31.9 1.6%
      REGN
      Regeneron Pharmaceuticals, Inc.
      		 $85.87B +8.1% +20.8% 20.7 3.3%
      ARGX
      Argenx SE
      		 $64.66B +23.6% — — 2.1%
      CSLLY
      Csl Ltd
      		 $57.97B — — — 0.0%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Reducing
      Holders
      101
      % held
      18.4%
      Net QoQ
      -2.4M sh
      Top holder
      BlackRock, Inc.
      Held Float
      View
      Held by Funds
      Fund positions
      77
      View
      Short & Settlement
      Short Interest Rising
      Shares short
      3.9M
      Days to cover
      7.5d
      Change
      +162.9K sh
      View
      Short Volume
      Short vol %
      48%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      70
      Value
      $159
      As of
      Jul 30, 2026
      View
      Off-Exchange
      Off-exchange %
      45.6%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Financials
      Financials
      Revenue (FY)
      $52.7M
      Net income (FY)
      $-6.6M
      EPS diluted
      $-0.08
      View
      Filings
      SEC Filings
      Latest
      8-K
      Filed
      Aug 12, 2026
      This year
      14
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View
      Investor Relations
      Latest news
      Protalix BioTherapeutics Reports…
      Published
      Aug 12, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      PLX +7.2% +0.4% -21.5% +0.4% +32.2%
      SPY -1.4% +3.6% +11.6% +2.5% +12.3%
      vs SPY +8.6% -3.2% -33.0% -2.1% +19.9%
      Key facts CIK 1006281 CUSIP 74365A309 13F (30d) 91 filings 89 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)